Rapport Therapeutics, Inc. Selling, General and Administrative Expense
Rapport Therapeutics, Inc. (RAPP) reported Selling, General and Administrative Expense of $9.39 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:SellingGeneralAndAdministrativeExpense · last filed 2026-08-05
- Rapport Therapeutics, Inc. selling, general and administrative expense for the quarter ending 2026-06-30 was $9.39M, a 37.79% increase year-over-year.
- Rapport Therapeutics, Inc. selling, general and administrative expense for the quarter ending 2026-03-31 was $11.50M, a 52.59% increase year-over-year.
- Rapport Therapeutics, Inc. selling, general and administrative expense for the quarter ending 2025-06-30 was $6.82M.
- Rapport Therapeutics, Inc. selling, general and administrative expense for the quarter ending 2025-03-31 was $7.54M.
| Period end | Selling, General and Administrative Expense 3 month | Selling, General and Administrative Expense 6 month |
|---|---|---|
| 2026-06-30 | $9.39M 10-Q · filed 2026-08-05 | $20.89M 10-Q · filed 2026-08-05 |
| 2026-03-31 | $11.50M 10-Q · filed 2026-05-07 | |
| 2025-06-30 | $6.82M 10-Q · filed 2026-08-05 | $14.35M 10-Q · filed 2026-08-05 |
| 2025-03-31 | $7.54M 10-Q · filed 2026-05-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |